SS Innovations International Inc. (NASDAQ: SSII) is positioning itself as a key player in the emerging field of telerobotic surgery, according to a recent MedTech Dive report that examined the technology's global progress and the regulatory and infrastructure challenges it faces. The article highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers, underscoring the company's growing relevance in the surgical robotics market. For investors, the company's expanding clinical experience and international footprint signal potential for significant growth as remote procedures gain acceptance.
As of September 28, 2026, SS Innovations had reported 195 robotic telesurgeries using its SSi Mantra system, including cardiac procedures and long-distance operations. The company's installed base reached 244 SSi Mantra systems, up 45% from the end of 2025, while cumulative procedures totaled 14,503. These figures demonstrate not only adoption but also the system's versatility across complex specialties. The SSi Mantra has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka, and a new program established at HCG Hospital in Ahmedabad.
In an interview with MedTech Dive, CEO Dr. Sudhir Srivastava, a cardiac surgeon, explained that robotic surgery is inherently a form of teleoperation. He noted that the central technical question is how much distance can be introduced without compromising responsiveness. This insight is critical as the medical community debates the feasibility and safety of remote procedures. SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking, which would allow the system to enter additional international markets. Such approvals could accelerate adoption and validate the technology on a global scale.
The broader interest in telerobotic surgery is putting SS Innovations International (NASDAQ: SSII) and its founder in an increasingly relevant part of the market. A recent MedTech Dive report, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology's development and the regulatory and infrastructure questions surrounding remote surgery. For those following the sector, the full article is available at https://ibn.fm/4ZLvL, and additional details can be found in the company's newsroom at https://ibn.fm/SSII.
MissionIR, a specialized communications platform, distributes news and updates for companies like SS Innovations. It operates as part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. For more information, visit MissionIR. These platforms help amplify the visibility of companies like SS Innovations as they reach key milestones. As telerobotic surgery continues to evolve, SS Innovations' progress with the SSi Mantra system and its pursuit of regulatory clearances will be important indicators of whether remote procedures become a standard part of surgical care worldwide.
